Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Gestoden: An Innovative Progestogen

  • Conference paper
Female Contraception

  • 144 Accesses

Abstract

Case reports and epidemiological retrospective case control studies suggested an increased cardiovascular risk associated with the oral contraceptive pill (OC) soon after its introduction; These findings prompted the initiation of three large epidemiological prospective cohort studies: in the United Kingdom those of the Royal College of General Practitioners (RCGP) and the Oxford Family Planning Association and in the United States the Walnut Creek Contraceptive Study. All started in 1968, at a time when older high-dose preparations were those commonly used [1, 2, 3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Layde P, Beral V (1981) Further analyses of mortality in oral contraceptive users. Lancet l(8219):541–546

    Google Scholar 

  2. Petitti DB et al. (1979) Risk of vascular disease in women smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 242 11:1150–1154

    Article  PubMed  CAS  Google Scholar 

  3. Vessey MP, McPherson K, Yeaytes D (1981) Mortality in oral contraceptive users. Lancet 1 (8219): 549–550

    Article  PubMed  CAS  Google Scholar 

  4. Engel HJ, Engel E, Lichtlen P (1985) Koronarsklerose und Herzinfarkt bei jungen Frauen. Muench Med Wochenschr 127, 16:415–417

    Google Scholar 

  5. Mann JI, Inman WHW (1975) Oral contraceptives and death from myocardial infarction. Br Med J [Clin Res] 2:245–248

    Article  CAS  Google Scholar 

  6. Hoppe G (1986) The pill, the heart and HDL: facts and fictions. Adv Contracept 2, 3:405–411

    Article  PubMed  CAS  Google Scholar 

  7. Vessey M et al. (1986) Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J [Clin Res] 292, 6519:526

    Article  CAS  Google Scholar 

  8. Vessey MP, Lawless M, Yeates D (1984) Oral contraceptives and stroke: findings in a large prospective study. Br Med J [Clin Res] 289 (6444):530–531

    Article  CAS  Google Scholar 

  9. Porter JB, Hunter JR, Danillson DA, Jick H, Stergachis A (1982) Oral contraceptives and nonfatal vascular disease - recent experience. Obstet Gynecol 59:299–302

    PubMed  CAS  Google Scholar 

  10. Porter JB, Hunter JR, Jick H, Stergachis A (1985) Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 66, 1:1–4

    PubMed  CAS  Google Scholar 

  11. Khaw Kay-Tee, Peart WS (1982) St. Mary’s Hospital Medical School, London, U.K. Blood pressure and contraceptive use. Br Med J [Clin Res] 285:403–407

    Article  Google Scholar 

  12. Ottossen U-B (1984) Oral progesterone and estrogen-progestogen therapy. Acta Obstet Gynecol Scand [Suppl] 127:1–37

    Article  Google Scholar 

  13. Varma TR (1983) Effect of oestrogen replacement therapy on blood coagulation factors in postmenopausal women. Int J Gynaecol Obstet 4, 21:291–296

    Article  Google Scholar 

  14. Larsson-Cohn U, Fahraens L, Wallentin L, Zador G (1981) Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril 35, 2:172–179

    PubMed  CAS  Google Scholar 

  15. Cullberg G, Dovre P, Lindstedt G, Steffensen K (1982) On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives. Acta Obstet Gynecol Scand [Suppl] 111:47–54

    Article  Google Scholar 

  16. Losert W, Casals-Stenzel J, Buse M (1985) Progestogens with antimineralocorticoid activity. Arzneimittelforschung 35 (1), 2:459–471

    Google Scholar 

  17. Wambach G (1986) Wie beeinflussen Gestagene den Natriumhaushalt? Fortschr Med 104, 29:37–40

    Google Scholar 

  18. Bruni V et al. (1986) Proceedings 1st International Congress on Gynecology and Endocrinology Madonna di Campiglio.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Berlimed, Philippine Cop., PO Box 331, MCC, 1299 Makapi, Metro, Manila, Philippines

    G. Hoppe

Authors
  1. G. Hoppe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Division of Gynecological Endocrinology, Women’s Hospital, University of Heidelberg, Voßstr. 9, D-6900, Heidelberg, Germany

    Benno Runnebaum , Thomas Rabe  & Ludwig Kiesel ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hoppe, G. (1988). Gestoden: An Innovative Progestogen. In: Runnebaum, B., Rabe, T., Kiesel, L. (eds) Female Contraception. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73790-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73790-9_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73792-3

  • Online ISBN: 978-3-642-73790-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation